Replies to post #107901 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

That kind of genetic patient selection is a doubled edged sword

I am thinking that Dr. M has a different plan as he researches pts genetics/DNA/results. Does he realize that one size A2-73 does not fit all? Is he working to optimize the NEXT version of A2-73 where a kind of DNA/periodic table will be used in future medical practice to treat CNS diseases? In the short term A2-73 will act as tube sock martialing ground for pts. Followed by custom directed dosages of the right stuff?

I know it is a fantasy but IMO that is how the learning process works and he is already way out in front of all of us. He is already defining what future medical practices will be doing, IMO.